Please login to the form below

Not currently logged in
Email:
Password:

BiTE

This page shows the latest BiTE news and features for those working in and with pharma, biotech and healthcare.

Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies

Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies

Amgen already has its own antibody technology – known as BiTE – which enables the identification and development of bispecific T cell engager antibodies. ... Teneobio’s own novel T cell engager platform will complement the BiTE platform, Amgen said

Latest news

More from news
Approximately 1 fully matching, plus 104 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 19 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 19 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Oxford PharmaGenesis

Oxford PharmaGenesis is an independently owned HealthScience communications consultancy, providing services to the healthcare industry, professional societies and patient groups....

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....